Naimish Patel, M.D., appointed to Chief Medical Officer

医学博士Naimish Patel被任命为首席医疗官

Julianne Bruno, M.B.A., promoted to Chief Operating Officer

工商管理硕士朱利安·布鲁诺晋升为首席运营官

ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024.

瑞士祖格和波士顿，2024年5月23日（环球通讯社）--专注于为严重疾病开发转化基因药物的生物制药公司CRISPR Therapeutics（纳斯达克：CRSP）今天宣布任命医学博士奈米什·帕特尔为首席医疗官，自2024年5月28日起生效。

Dr. Patel is an experienced drug developer who has worked across a wide range of disease areas, including his most recent leadership role as the Global Development Therapeutic Area Head of Immunology and Inflammation at Sanofi. In addition, the Company also announced the promotion of Julianne Bruno, M.B.A., to Chief Operating Officer, effective as of May 23, 2024.

帕特尔博士是一位经验丰富的药物开发人员，曾在广泛的疾病领域工作，包括他最近担任赛诺菲全球发展治疗领域免疫学和炎症负责人的领导角色。此外，该公司还宣布，自2024年5月23日起，将工商管理硕士朱利安·布鲁诺晋升为首席运营官。

She currently serves as the Company’s Senior Vice President and Head of Programs & Portfolio Management..

她目前担任公司高级副总裁兼项目与投资组合管理主管。。

“I’m thrilled to welcome a transformational leader of Naimish’s caliber to the executive team at CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics. “His extensive drug development experience and proven leadership will be critical as we expand our portfolio and advance multiple assets in our pipeline.”.

CRISPR Therapeutics首席执行官兼主席SamarthKulkarni博士表示：“我很高兴欢迎Naimish的转型领导者加入CRISPR Therapeutics的执行团队。”。“他丰富的药物开发经验和久经考验的领导力将对我们扩大投资组合和推进多种资产至关重要。”。

Dr. Kulkarni added: “Additionally, I am very pleased to announce Julie's promotion and I look forward to her continued contributions as we scale the Company. Since joining CRISPR Therapeutics in 2019, Julie has been a valuable member of the leadership team and has led several important and impactful cross-functional initiatives including our collaboration with Vertex.

Kulkarni博士补充道：“此外，我很高兴宣布Julie的晋升，我期待着她在我们扩大公司规模时继续做出贡献。自2019年加入CRISPR Therapeutics以来，Julie一直是领导团队的重要成员，并领导了几项重要且有影响力的跨职能计划，包括我们与Vertex的合作。

With this strengthened executive team, combined with our significant progress to date, CRISPR Therapeutics remains well positioned to rapidly advance our programs and deliver on our mission to develop transformative medicines for patients suffering from serious diseases.”.

有了这个加强的执行团队，再加上我们迄今为止取得的重大进展，CRISPR Therapeutics仍然处于有利地位，可以迅速推进我们的计划，并履行我们为患有严重疾病的患者开发变革性药物的使命。”。

“CRISPR Therapeutics' compelling and innovative platform, exciting clinical assets and impressive manufacturing capabilities position the Company to potentially bring several transformative therapies to patients with significant unmet medical need,” said Naimish Patel, M.D., “I am incredibly excited to join the CRISPR leadership team and help bring these therapies to patients in need.”.

“CRISPR Therapeutics引人注目的创新平台，令人兴奋的临床资产和令人印象深刻的制造能力使该公司有可能为严重未满足医疗需求的患者带来几种变革性疗法，”医学博士Naimish Patel说，“我非常高兴加入CRISPR领导团队，帮助将这些疗法带给有需要的患者。”。

Dr. Patel joins CRISPR Therapeutics from Sanofi, where he most recently served as the Global Development Therapeutic Area Head of Immunology and Inflammation. Previously, he was the Global Program Head for Dupilumab at Sanofi, leading multiple waves of indication expansion including chronic obstructive pulmonary disease and eosinophilic esophagitis.

Patel博士加入了赛诺菲的CRISPR Therapeutics，最近他在赛诺菲担任全球发展治疗领域免疫学和炎症负责人。此前，他是赛诺菲Dupilumab全球项目负责人，领导了包括慢性阻塞性肺病和嗜酸性食管炎在内的多波适应症扩展。

During his time at Sanofi, Dr. Patel led the development of an industry-leading pipeline across key therapeutic areas including respiratory, dermatology, gastroenterology, and rheumatology. He also oversaw key business development and M&A activities during a rapid phase of pipeline expansion. Dr. Patel is a pulmonary and critical care physician with an extensive background in translational medicine and clinical trials..

在赛诺菲任职期间，帕特尔博士领导开发了一条行业领先的管道，跨越呼吸、皮肤病、肠胃病和风湿病等关键治疗领域。他还监督了管道扩张快速阶段的关键业务发展和并购活动。Patel博士是一名肺部和重症监护医生，在转化医学和临床试验方面拥有广泛的背景。。

Dr. Patel received a B.S. in Mechanical Engineering from MIT and an M.D. from McGill University. He completed his internal medicine training at Columbia-Presbyterian Hospital and his fellowship training in Pulmonary and Critical Medicine at Harvard Medical School. After completing his fellowship, Dr.

帕特尔博士拥有麻省理工学院机械工程学士学位和麦吉尔大学医学博士学位。他在哥伦比亚长老会医院完成了内科培训，并在哈佛医学院完成了肺部和重症医学的奖学金培训。完成奖学金后，博士。

Patel was a member of the faculty at Harvard and Beth Israel Deaconess Medical Center where he led an NIH-funded lab in translational immunology focused on innate defense functions of the lungs. He previously held positions in clinical development and discovery project leadership at AstraZeneca and Vertex Pharmaceuticals..

帕特尔是哈佛大学和贝斯以色列女执事医学中心的教员，在那里他领导了一个由美国国立卫生研究院资助的转化免疫学实验室，该实验室专注于肺部的先天防御功能。他曾在阿斯利康和Vertex制药担任临床开发和发现项目领导职务。。

Julianne Bruno, M.B.A., has served as Senior Vice President and Head of Programs & Portfolio Management at CRISPR Therapeutics since March 2023. During her time at CRISPR Therapeutics since joining the Company in April 2019, she has taken on positions of increasing responsibility, including leading the hemoglobinopathies partnership with Vertex through the early clinical stage through approval.

JulianneBruno，MBA，自2023年3月起担任CRISPR Therapeutics的高级副总裁兼项目与投资组合管理负责人。自2019年4月加入CRISPR Therapeutics以来，她在CRISPR Therapeutics任职期间，承担了越来越大的责任，包括通过批准在早期临床阶段领导与Vertex的血红蛋白病合作关系。

In addition, she has been responsible for program leadership of our immuno-oncology assets and the program management function across our franchises. Prior to joining CRISPR Therapeutics, Ms. Bruno worked at McKinsey & Company from August 2015 to March 2019 where she was a leader in the biotech practice and served a number of biotechnology companies on a wide range of commercial topics.

此外，她还负责我们免疫肿瘤学资产的项目领导以及整个特许经营范围内的项目管理职能。在加入CRISPR Therapeutics之前，布鲁诺女士于2015年8月至2019年3月在麦肯锡公司工作，在那里她是生物技术实践的领导者，并为多家生物技术公司提供了广泛的商业主题服务。

She received her M.B.A. from The Wharton School and also holds an A.B. from Princeton University..

她获得了沃顿商学院的工商管理硕士学位，还获得了普林斯顿大学的工商管理硕士学位。。

About CRISPR Therapeutics

关于CRISPR治疗

Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune and rare diseases.

自十多年前成立以来，CRISPR Therapeutics已经从一家推进基因编辑领域项目的研究阶段公司转变为一家最近庆祝首次基于CRISPR的疗法获得历史性批准的公司，并且在包括血红蛋白病，肿瘤学，再生医学，心血管疾病，自身免疫性疾病和罕见疾病在内的广泛疾病领域拥有多种候选产品组合。

CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel) was approved in some countries to treat eligible patients with either of those conditions.

CRISPR Therapeutics于2018年将有史以来第一种CRISPR/Cas9基因编辑疗法推进临床，以研究镰状细胞病或输血依赖性β地中海贫血的治疗，并从2023年底开始，CASGEVY™（exagamglogene autotemcel）在一些国家被批准治疗符合条件的患者。

The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals.

诺贝尔奖得主CRISPR science彻底改变了生物医学研究，代表了一种强大的临床验证方法，有可能创造一类新的潜在转化药物。为了加速和扩大其努力，CRISPR Therapeutics与包括拜耳和Vertex Pharmaceuticals在内的领先公司建立了战略合作伙伴关系。

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com..

CRISPR Therapeutics AG总部位于瑞士祖格，其全资美国子公司CRISPR Therapeutics，Inc.，研发业务位于马萨诸塞州波士顿和加利福尼亚州旧金山，业务办事处位于英国伦敦。要了解更多信息，请访问www.crisprtx.com。。

CRISPR THERAPEUTICS® standard character mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. The CASGEVY™ word mark and design are trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners..

CRISPR THERAPEUTICS®标准字符标记和设计徽标是CRISPR THERAPEUTICS AG的商标和注册商标。CASGEVY™单词标记和设计是Vertex Pharmaceuticals Incorporated的商标。所有其他商标和注册商标均为其各自所有者的财产。。

CRISPR Therapeutics Forward-Looking Statement

CRISPR治疗学前瞻性声明

This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Drs. Kulkarni and Patel in this press release, as well as statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) its plans for and its preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data generally; (ii) the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; (iii) the sufficiency of its cash resources; (iv) the expected benefits of its collaborations; and (v) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies.

本新闻稿可能包含1995年《私人证券诉讼改革法案》（经修订）含义内的一些“前瞻性声明”，包括Kulkarni博士和Patel博士在本新闻稿中的声明，以及关于CRISPR Therapeutics对以下任何或所有方面的期望的声明：（i）其临床前研究，临床试验和管道产品和计划的计划，包括但不限于制造能力，此类研究和试验的状态，可能扩展到新的适应症和对数据的期望；（ii）正在进行和计划进行的临床试验将产生的数据，以及将这些数据用于设计和启动进一步临床试验的能力；（iii）其现金资源是否充足；（iv）合作的预期收益；（v）CRISPR/Cas9基因编辑技术和疗法的治疗价值，发展和商业潜力。

Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk.

在不限制上述内容的情况下，“相信”，“预期”，“计划”，“预期”等词语旨在识别前瞻性陈述。请注意，前瞻性陈述本质上是不确定的。尽管CRISPR Therapeutics认为这些陈述是基于其业务和运营知识范围内的合理假设，但前瞻性陈述既不是承诺也不是保证，它们必然会受到高度不确定性和风险的影响。

Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the efficacy and safety results from ongoin.

由于各种风险和不确定性，实际绩效和结果可能与前瞻性声明中的预测或建议存在重大差异。这些风险和不确定性包括：ongoin的有效性和安全性结果。

Investor Contact:

投资者联系人：

Susan Kim

苏珊·金

+1-617-307-7503

+1-617-307-7503

susan.kim@crisprtx.com

susan.kim@crisprtx.com

Media Contact:

媒体联系人：

Rachel Eides

瑞秋·艾德斯

+1-617-315-4493

+1-617-315-4493

rachel.eides@crisprtx.com

rachel.eides@crisprtx.com